Back

Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 4 Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Craig Coleman

University of Connecticut, Storrs (United States of America)

8 More presentations in this session

Presentation thumbnail
Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding
Doctor T. Chao (Taipei, TW)
Abstract
Presentation thumbnail
Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study
Doctor P. Rasmussen (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study
Professor J. Hartikainen (Kuopio, FI)
Abstract Slides
Presentation thumbnail
Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke
Associate Professor S. Choi (Daegu, KR)
Abstract Slides
Presentation thumbnail
Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban
Doctor G. Vanerio (Montevideo, UY)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources